I am surprised this stock is still very much under the radar....

I am surprised this stock is still very much under the radar. Some highlights from the investor presentation on 20th Feb 14 (date of the ASX listing) include:

"Simavita has developed and commercialised the world’s first and only instrumented incontinence assessment medical 
device-SIM™."
"Aging global population - an investment mega-trend"
"Commercialized product - FDA clearance in place"
"3 granted patents"
"Global coverage pending"

These are only a few highlights. The entire document is a good read.

The company listed on the TXSV (Canada, code SV) on 6th Dec 13.
I know incontinence is a boring subject but it's a very real, albeit secretive, issue for patients and their carers.

This company appears to have a solution which is already being sold in Australia with US distribution starting in Q1 2014 and is advancing global distribution discussions in Canada and the EU.

In summary they have a ready-to-market, in demand product already being distributed and with seemingly no competitors at this stage.
It's already had a run and pulled back a bit since listing but at .88c it seem very undervalued. It's very illiquid but I think that will change as global sales start to pickup.
I have yet to take up a position and am curious as to what others think about this stock.
Sue